|
1
|
Dent AL, Shaffer AL, Yu X, Allman D and
Staudt LM: Control of inflammation, cytokine expression, and
germinal center formation by BCL-6. Science. 276:589–592. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Basso K and Dalla-Favera R: Roles of
BCL6 in normal and transformed germinal center B cells.
Immunol Rev. 247:172–183. 2012.
|
|
3
|
Cattoretti G, Chang CC, Cechova K, Zhang
J, Ye BH, Falini B, Louie DC, Offit K, Chaganti RS and Dalla-Favera
R: BCL-6 protein is expressed in germinal-center B cells. Blood.
86:45–53. 1995.PubMed/NCBI
|
|
4
|
Onizuka T, Moriyama M, Yamochi T, Kuroda
T, Kazama A, Kanazawa N, Sato K, Kato T, Ota H and Mori S: BCL-6
gene product, a 92- to 98-kD nuclear phosphoprotein, is highly
expressed in germinal center B cells and their neoplastic
counterparts. Blood. 86:28–37. 1995.
|
|
5
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell
JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB,
Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD,
Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC,
Botstein D, Brown PO and Staudt LM: Distinct types of diffuse large
B-cell lymphoma identified by gene expression profiling. Nature.
403:503–511. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lossos IS, Jones CD, Warnke R, Natkunam Y,
Kaizer H, Zehnder JL, Tibshirani R and Levy R: Expression of a
single gene, BCL-6, strongly predicts survival in patients
with diffuse large B-cell lymphoma. Blood. 98:945–951.
2001.PubMed/NCBI
|
|
7
|
Dhordain P, Albagli O, Ansieau S, Koken
MH, Deweindt C, Quief S, Lantoine D, Leutz A, Kerckaert JP and
Leprince D: The BTB/POZ domain targets the LAZ3/BCL6
oncoprotein to nuclear dots and mediates homomerisation in vivo.
Oncogene. 11:2689–2697. 1995.PubMed/NCBI
|
|
8
|
Jardin F, Ruminy P, Bastard C and Tilly H:
The BCL6 proto-oncogene: a leading role during germinal
center development and lymphomagenesis. Pathol Biol. 55:73–83.
2007.
|
|
9
|
Okabe S, Fukuda T, Ishibashi K, Kojima S,
Okada S, Hatano M, Ebara M, Saisho H and Tokuhisa T: BAZF, a novel
Bcl6 homolog, functions as a transcriptional repressor. Mol
Cell Biol. 18:4235–4244. 1998.
|
|
10
|
Davies JM, Hawe N, Kabarowski J, Brand NJ,
Leprince D, Dhordain P, Cook M, Morriss-Kay G and Zelent A: Novel
BTB/POZ domain zinc-finger protein, LRF, is a potential target of
the LAZ-3/BCL-6 oncogene. Oncogene. 18:365–375. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dhordain P, Albagli O, Honore N, Guidez F,
Lantoine D, Schmid M, The HD, Zelent A and Koken MH: Colocalization
and heteromerization between the two human oncogene POZ/zinc finger
proteins, LAZ3 (BCL6) and PLZF. Oncogene. 19:6240–6250.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Logarajah S, Hunter P, Kraman M, Steele D,
Lakhani S, Bobrow L, Venkitaraman A and Wagner S: BCL-6 is
expressed in breast cancer and prevents mammary epithelial
differentiation. Oncogene. 22:5572–5578. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bos R, van Diest PJ, van der Groep P,
Greijer AE, Hermsen MA, Heijnen I, Meijer GA, Baak JP, Pinedo HM,
van der Wall E and Shvarts A: Protein expression of B-cell lymphoma
gene 6 (BCL-6) in invasive breast cancer is associated with cyclin
D1 and hypoxia-inducible factor-1α (HIF-1α). Oncogene.
22:8948–8951. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Walters MP, McPhail ED, Law ME and Folpe
AL: BCL-6 expression in mesenchymal tumours: an immunohistochemical
and fluorescence in situ hybridisation study. J Clin Pathol.
64:866–869. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suehiro Y and Hinoda Y: Genetic and
epigenetic changes in aberrant crypt foci and serrated polyps.
Cancer Sci. 99:1071–1076. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Di Gregorio C, Losi L, Fante R, Modica S,
Ghidoni M, Pedroni M, Tamassia MG, Gafà L, Ponz de Leon M and
Roncucci L: Histology of aberrant crypt foci in the human colon.
Histopathology. 30:328–334. 1997.
|
|
17
|
Roncucci L, Pedroni M, Vaccina F, Benatti
P, Marzona L and De Pol A: Aberrant crypt foci in colorectal
carcinogenesis. Cell and crypt dynamics. Cell Prolif. 33:1–18.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takayama T, Miyanishi K, Hayashi T,
Kukitsu T, Takanashi K, Ishiwatari H, Kogawa T, Abe T and Niitsu Y:
Aberrant crypt foci: detection, gene abnormalities, and clinical
usefulness. Clin Gastroenterol Hepatol. 3(Suppl 1): S42–S45. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roncucci L, Mora E, Mariani F, Bursi S,
Pezzi A, Rossi G, Pedroni M, Luppi D, Santoro L, Monni S, Manenti
A, Bertani A, Merighi A, Benatti P, Di Gregorio C and de Leon PM:
Myeloperoxidase-positive cell infiltration in colorectal
carcinogenesis as indicator of colorectal cancer risk. Cancer
Epidemiol Biomarkers Prev. 17:2291–2297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sena P, Roncucci L, Marzona L, Mariani F,
Maffei S, Manenti A and De Pol A: Altered expression of apoptosis
biomarkers in human colorectal microadenomas. Cancer Epidemiol
Biomarkers Prev. 19:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hirata Y, Ogasawara N, Sasaki M, Mizushima
T, Shimura T, Mizoshita T, Mori Y, Kubota E, Wada T, Tanida S,
Kataoka H, Kamiya T, Higashiyama S and Joh T: BCL6
degradation caused by the interaction with the C-terminus of
pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J
Cancer. 100:1320–1329. 2009. View Article : Google Scholar
|
|
22
|
Roncucci L, Medline A and Bruce WR:
Classification of aberrant crypt foci and microadenomas in human
colon. Cancer Epidemiol Biomarkers Prev. 1:57–60. 1991.PubMed/NCBI
|
|
23
|
Takayama T, Katsuki S, Takahashi Y, Ohi M,
Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H and Niitsu Y:
Aberrant crypt foci of the colon as precursors of adenoma and
cancer. N Engl J Med. 339:1277–1284. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Korinek V, Barker N, Morin PJ, van Wichen
D, de Weger R, Kinzler KW, Vogelstein B and Clevers H: Constitutive
transcriptional activation by a β-catenin-Tcf complex in
APC−/−colon carcinoma. Science. 275:1784–1787. 1997.
|
|
25
|
Morin PJ, Sparks AB, Korinek V, Barker N,
Clevers H, Vogelstein B and Kinzler KW: Activation of β-catenin-Tcf
signalling in colon cancer by mutations in β-catenin or APC.
Science. 275:1787–1790. 1997.
|
|
26
|
Pinto D and Clevers H: Wnt, stem cells and
cancer in the intestine. Biol Cell. 97:185–196. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saadi A, Shannon NB, Lao-Sirieix P,
O’Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M,
Save V, Novelli M, Balkwill F and Fitzgerald RC: Stromal genes
discriminate preinvasive from invasive disease, predict outcome,
and highlight inflammatory pathways in digestive cancers. Proc Natl
Acad Sci USA. 107:2177–2182. 2010. View Article : Google Scholar
|
|
28
|
Bilalovic N, Blystad AK, Golouh R, Nesland
JM, Selak I, Trinh D and Torlakovic E: Expression of bcl-6 and CD10
protein is associated with longer overall survival and time to
treatment failure in follicular lymphoma. Am J Clin Pathol.
121:34–42. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berglund M, Thunberg U, Amini RM, Book M,
Roos G, Erlanson M, Linderoth J, Dictor M, Jerkeman M,
Cavallin-Ståhl E, Sundström C, Rehn-Eriksson S, Backlin C, Hagberg
H, Rosenquist R and Enblad G: Evaluation of immunophenotype in
diffuse large B-cell lymphoma and its impact on prognosis. Mod
Pathol. 18:1113–1120. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Levy O, Deangelis LM, Filippa DA, Panageas
KS and Abrey LE: Bcl-6 predicts improved prognosis in primary
central nervous system lymphoma. Cancer. 112:151–156. 2008.
View Article : Google Scholar : PubMed/NCBI
|
